在复发性子宫癌肉瘤中对Wee1抑制剂阿达沃谢蒂布进行第二阶段研究
Stephanie Cham1, Niya Xiong2, Nabihah Tayob2
1Department of Obstetrics and Gynecology & Reproductive Sciences, University of California San Francisco, San Francisco, CA, United States of America.
Gynecologic oncology reports
|July 18, 2025
概括
在TP53突变的复发性子宫癌 (UCS) 中,Adavosertib的活性有限. 对这种侵袭性癌症需要进一步研究分子变化和组合疗法.
科学领域:
- 在瘤学瘤学.
- 妇科瘤学 妇科瘤学
- 分子瘤学分子瘤学
背景情况:
- 子宫癌 (UCS) 是一种罕见的,具有高复发率和不良预后的侵袭性癌症,需要新的治疗策略.
- 在90%以上的UCS病例中,TP53突变是普遍存在的,这表明潜在的治疗脆弱性.
- 由于其在细胞循环调节中的作用和UCS频繁变化的作用,Wee1激酶是潜在的目标.
研究的目的:
- 为了评估Adavosertib的疗效和安全性,Wee1激酶抑制剂,在患有复发性或持久性子宫癌的患者中.
- 评估客观应答率 (ORR) 和6个月无进展生存期 (PFS) 作为共同初级终点.
主要方法:
- 一项II期,单一机构研究招募了9名患有持续或复发性UCS的患者,并确认了TP53的改变.
- 患者在21天的循环中接受阿达沃谢蒂布 (每天300毫克),直到疾病进展.
- 通过针对性下一代测序来评估分子变化.
主要成果:
- 阿达沃谢蒂布的活性有限,ORR为22.2% (2部分反应) 和33.3%的稳定疾病.
- 中位数PFS为2.7个月. 与治疗相关的不良事件发生在88.9%的患者中,主要是腹和疲劳.
- 由于赞助商的决定,该研究在9名患者被录取后提前中止.
结论:
- 在这项针对TP53突变UCS的II期试验中,Adavosertib显示出有限的临床活性.
- 研究分子变化和组合策略对于推进UCS治疗至关重要.
- 进一步的研究是有必要的,以确定UCS更有效的治疗方法.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.2K
相关概念视频
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:07Tumor Progression
6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K